Moderna, Inc.

NASDAQ

Market Cap.

9.56B

Avg. Volume

10.42M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Moderna, Inc.

Moderna, Inc. News

Moderna, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
modernatx.com

About Moderna, Inc.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc. Earnings & Revenue

Moderna, Inc. Financials

Table Compare

Compare MRNA metrics with:

   

Earnings & Growth

MRNA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

MRNA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

MRNA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

MRNA

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Moderna, Inc. Income

Moderna, Inc. Balance Sheet

Moderna, Inc. Cash Flow

Moderna, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsSell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Moderna, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Moderna, Inc. Executives

NameRole
Mr. Stephane BancelChief Executive Officer & Director
Dr. Stephen Hoge M.D.President
Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate Secretary
Mr. James M. MockChief Financial Officer
Dr. Melanie Ivarsson M.B.A., Ph.D.Chief Development Officer
NameRoleGenderDate of BirthPay
Mr. Stephane BancelChief Executive Officer & DirectorMale19734.57M
Dr. Stephen Hoge M.D.President19762.55M
Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate SecretaryFemale19711.61M
Mr. James M. MockChief Financial OfficerMale19771.45M
Dr. Melanie Ivarsson M.B.A., Ph.D.Chief Development Officer

--

Moderna, Inc. Insider Trades

Date30 Apr
NameTallett Elizabeth E
RoleDirector
TransactionAcquired
TypeA-Award
Shares19134
Date30 Apr
NameTallett Elizabeth E
RoleDirector
TransactionAcquired
TypeA-Award
Shares4058
Date30 Apr
NameSAGAN PAUL
RoleDirector
TransactionAcquired
TypeA-Award
Shares25512
Date30 Apr
NameRubenstein David M.
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares677
Date30 Apr
NameRubenstein David M.
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares677
DateNameRoleTransactionTypeShares
30 AprTallett Elizabeth EDirectorAcquiredA-Award19134
30 AprTallett Elizabeth EDirectorAcquiredA-Award4058
30 AprSAGAN PAULDirectorAcquiredA-Award25512
30 AprRubenstein David M.DirectorAcquiredM-Exempt677
30 AprRubenstein David M.DirectorDisposedM-Exempt677

Discover More

Streamlined Academy

Moderna, Inc.

NASDAQ

Market Cap.

9.56B

Avg. Volume

10.42M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Moderna, Inc. News

Moderna, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Moderna, Inc. Earnings & Revenue

Moderna, Inc. Income

Moderna, Inc. Balance Sheet

Moderna, Inc. Cash Flow

Moderna, Inc. Financials Over Time

Moderna, Inc. Executives

NameRole
Mr. Stephane BancelChief Executive Officer & Director
Dr. Stephen Hoge M.D.President
Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate Secretary
Mr. James M. MockChief Financial Officer
Dr. Melanie Ivarsson M.B.A., Ph.D.Chief Development Officer
NameRoleGenderDate of BirthPay
Mr. Stephane BancelChief Executive Officer & DirectorMale19734.57M
Dr. Stephen Hoge M.D.President19762.55M
Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate SecretaryFemale19711.61M
Mr. James M. MockChief Financial OfficerMale19771.45M
Dr. Melanie Ivarsson M.B.A., Ph.D.Chief Development Officer

--

Moderna, Inc. Insider Trades

Date30 Apr
NameTallett Elizabeth E
RoleDirector
TransactionAcquired
TypeA-Award
Shares19134
Date30 Apr
NameTallett Elizabeth E
RoleDirector
TransactionAcquired
TypeA-Award
Shares4058
Date30 Apr
NameSAGAN PAUL
RoleDirector
TransactionAcquired
TypeA-Award
Shares25512
Date30 Apr
NameRubenstein David M.
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares677
Date30 Apr
NameRubenstein David M.
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares677
DateNameRoleTransactionTypeShares
30 AprTallett Elizabeth EDirectorAcquiredA-Award19134
30 AprTallett Elizabeth EDirectorAcquiredA-Award4058
30 AprSAGAN PAULDirectorAcquiredA-Award25512
30 AprRubenstein David M.DirectorAcquiredM-Exempt677
30 AprRubenstein David M.DirectorDisposedM-Exempt677

Streamlined Academy

Website screenshot
HealthcareBiotechnology
modernatx.com

About Moderna, Inc.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Moderna, Inc.

Moderna, Inc. Financials

Table Compare

Compare MRNA metrics with:

   

Earnings & Growth

MRNA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

MRNA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

MRNA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

MRNA

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Moderna, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsSell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)